Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice

Current Rheumatology Reports

Volumn 12, Issue 4, 2010, Pages 264-271

  Mumtaz, Aizad ^a   Fitzgerald, Oliver ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Composite; CPDAI; Disease activity; GRAPPA; Psoriatic arthritis; Psoriatic disease; Response

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PSORALEN; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ARTERITIS; ARTHRITIS; ARTHROPATHY; BACKACHE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; DACTYLITIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; HAND DISEASE; HEALTH CARE ORGANIZATION; HUMAN; JOINT RADIOGRAPHY; JOINT SWELLING; LIMB PAIN; LIMB SWELLING; LYMPHEDEMA; NAIL DISEASE; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; REVIEW; SKIN DISEASE; SPINE DISEASE; SYNOVITIS; ULTRAVIOLET RADIATION; VALIDATION PROCESS; ARTHRITIS, PSORIATIC; CLINICAL PROTOCOL; SEVERITY OF ILLNESS INDEX;

ARTHRITIS, PSORIATIC; CLINICAL PROTOCOLS; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 77955983260     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0109-y     Document Type: Review

References (39)

1. DD Gladman C Antoni P Mease, et al. 2005 Psoriatic arthritis: epidemiology, clinical features, course, and outcome Ann Rheum Dis 64 Suppl 2 ii14 ii17 10.1136/ard.2004.032482 15708927
2. JM Moll V Wright 1973 Psoriatic arthritis Semin Arthritis Rheum 3 55 78 10.1016/0049-0172(73)90035-8 1:STN:280:DyaE3s3ls1Ghsw%3D%3D 4581554
3. DM Ashcroft AL Wan Po HC Williams CE Griffiths 1999 Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality Br J Dermatol 141 185 191 10.1046/j.1365-2133.1999.02963.x 1:STN:280: DyaK1Mzpsl2qtA%3D%3D 10468786
4. W Taylor D Gladman P Helliwell CASPAR Study Group, et al. 2006 Classification criteria for psoriatic arthritis: development of new criteria from a large international study Arthritis Rheum 54 2665 2673 10.1002/art.21972 16871531
5. P Rahman JT Elder 2005 Genetic epidemiology of psoriasis and psoriatic arthritis Ann Rheum Dis 64 Suppl 2 ii37 ii39 10.1136/ard.2004.030775 15708933 discussion ii40-ii41
6. DJ Veale C Ritchlin O FitzGerald, et al. 2005 Immunopathology of psoriasis and psoriatic arthritis Ann Rheum Dis 64 Suppl 2 ii26 ii29 10.1136/ard.2004.031740 15708930
7. DT Felson JJ Anderson M Boers, et al. 1995 American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 727 735 10.1002/art.1780380602 1:STN:280:DyaK2M3pvVSmtA%3D%3D 7779114
8. BF Leeb I Andel J Sautner, et al. 2007 The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients Arthritis Rheum 57 256 260 10.1002/art.22531 17330303 Owing to the bidimensional nature and statistical properties of the DAS-28, the authors raise questions about its use for assessment of PsA. They further stress the importance of a PsA-specific instrument to assess disease activity and response
9. DO Clegg DJ Reda E Mejias, et al. 1996 Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study Arthritis Rheum 39 2013 2020 10.1002/art.1780391210 1:CAS:528:DyaK2sXjt12ltg%3D%3D 8961906
10. DD Gladman BD Tom PJ Mease, et al. 2008 Response criteria for psoriatic arthritis: developing and comparing response criteria for PsA [abstract] Ann Rheum Dis 67 Suppl 2 526
11. VP Nell-Duxneuner TA Stamm KP Machold, et al. 2010 Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis Ann Rheum Dis 69 546 549 10.1136/ard.2009.117945 19762363
12. G Eberl A Studnicka-Benke H Hitzelhammer, et al. 2000 Development of a disease activity index for the assessment of reactive arthritis (DAREA) Rheumatology (Oxford) 39 148 155 10.1093/rheumatology/39.2.148 1:STN:280:DC%2BD3c7ptVSnsg%3D%3D
13. AF Kavanaugh CT Ritchlin GRAPPA Treatment Committee 2006 Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines J Rheumatol 33 1417 1421 16724373
14. DD Gladman P Helliwell PJ Mease, et al. 2004 Assessment of patients with psoriatic arthritis: a review of currently available measures Arthritis Rheum 50 24 35 10.1002/art.11417 14730596
15. PJ Mease CE Antoni DD Gladman WJ Taylor 2005 Psoriatic arthritis assessment tools in clinical trials Ann Rheum Dis 64 Suppl 2 ii49 ii54 10.1136/ard.2004.034165 15708937
16. DD Gladman PJ Mease V Strand, et al. 2007 Consensus on a core set of domains for psoriatic arthritis J Rheumatol 34 1167 1170 17477480 At OMERACT 8, various instruments used to assess PsA were reviewed. Following discussion at breakout groups, the group achieved consensus on six core domains: peripheral joint activity, skin activity, pain, patient global assessment, physical function, and health-related quality of life. In addition, the following domains were considered important but not mandatory: spinal disease, dactylitis, enthesitis, fatigue, nail disease, radiography, physician global assessment, and acute-phase reactants
17. A Mumtaz P Helliwell O FitzGerald, et al. 2009 Development of a Composite Psoriatic Disease Activity Index(CPDAI) Arthritis Rheum 60 10 Suppl s200
18. DD Gladman V Farewell D Buskila, et al. 1990 Reliability of measurements of active and damaged joints in psoriatic arthritis J Rheumatol 17 62 64 1:STN:280:DyaK3c7ovFSksQ%3D%3D 2313676
19. JF Fries P Spitz RG Kraines HR Holman 1980 Measurement of patient outcome in arthritis Arthritis Rheum 23 137 145 10.1002/art.1780230202 1:STN:280:DyaL3c7ltlGlsQ%3D%3D 7362664
20. T Fredriksson U Pettersson 1978 Severe psoriasis-oral therapy with a new retinoid Dermatologica 157 238 244 10.1159/000250839 1:STN:280: DyaE1M%2Fgtlymtg%3D%3D 357213
21. SR Feldman GG Krueger 2005 Psoriasis assessment tools in clinical trials Ann Rheum Dis 64 Suppl 2 ii65 ii68 10.1136/ard.2004.031237 15708941 discussion ii69-ii73
22. AY Finlay GK Khan 1994 Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use Clin Exp Dermatol 19 210 216 10.1111/j.1365-2230.1994.tb01167.x 1:STN:280:DyaK2czgs1OjtA%3D%3D 8033378
23. L Heuft-Dorenbosch A Spoorenberg A van Tubergen, et al. 2003 Assessment of enthesitis in ankylosing spondylitis Ann Rheum Dis 62 127 132 10.1136/ard.62.2.127 1:STN:280:DC%2BD3s%2FktlCqsQ%3D%3D 12525381
24. J Braun J Brandt J Listing, et al. 2002 Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial Lancet 359 1187 1193 10.1016/S0140-6736(02)08215-6 1:CAS:528:DC%2BD38XivVShsro%3D 11955536
25. DD Gladman RJ Cook C Schentag, et al. 2004 The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada J Rheumatol 31 1126 1131 15170925
26. PJ Healy PS Helliwell 2008 Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis Arthritis Rheum 59 686 691 10.1002/art.23568 18438903 Through an iterative process of data reduction, Healy and Helliwell devised a new index called the LEI. It involves assessment at six sites: bilateral lateral epicondyles of humerus, medical condyles of femur, and Achilles insertion. It demonstrated a good effect size compared with other instruments
27. D Kane L Stafford B Bresnihan O FitzGerald 2003 A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience Rheumatology (Oxford) 42 1460 1468 10.1093/rheumatology/keg384 1:STN:280:DC%2BD3srntFyhtw%3D%3D
28. MJ Battistone BJ Manaster DJ Reda, et al. 1998 Radiographic diagnosis of sacroiliitis-are sacroiliac views really better? J Rheumatol 25 2395 2401 1:STN:280:DyaK1M%2FnsVWntQ%3D%3D 9858436
29. I Olivieri L Barozzi L Favaro, et al. 1996 Dactylitis in patients with seronegative spondylarthropathy. Assessment by ultrasonography and magnetic resonance imaging Arthritis Rheum 39 1524 1528 10.1002/art.1780390912 1:STN:280:DyaK28vgvFSrsw%3D%3D 8814064
30. C Antoni GG Krueger K de Vlam IMPACT 2 Trial Investigators, et al. 2005 Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Ann Rheum Dis 64 1150 1157 10.1136/ard.2004.032268 1:CAS:528:DC%2BD2MXpslGmsrg%3D 15677701
31. PJ Healy PS Helliwell 2007 Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol 34 1302 1306 17309128 The authors have proposed a new instrument (Leeds Dactylitis Index). They undertook an open-label observational trial to compare the performance of this instrument with that of other available instruments
32. A Kavanaugh I McInnes P Mease, et al. 2009 Golimumab, a new human tumor necrosis factor alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study Arthritis Rheum 60 976 986 10.1002/art.24403 1:CAS:528:DC%2BD1MXltFenu7g%3D 19333944 This multicenter, randomized, double-blind, placebo-controlled trial was conducted to assess the efficacy and safety of golimumab in patients with active PsA. There was significantly greater improvement in the dactylitis severity score with golimumab, 100 mg
33. DD Gladman B Brubacher D Buskila, et al. 1993 Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis Clin Invest Med 16 1 7 1:STN:280:DyaK3s3itlegsQ%3D%3D 8467576
34. J Braun T Pham J Sieper ASAS Working Group, et al. 2003 International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis Ann Rheum Dis 62 817 824 10.1136/ard.62.9.817 1:CAS:528:DC%2BD3sXns1SisLg%3D 12922952
35. JC Davis Jr D Revicki DM van der Heijde, et al. 2007 Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study Arthritis Rheum 57 1050 1057 10.1002/art.22887 17665483 This randomized controlled study evaluated the impact of adalimumab on health-related quality of life in patients with active ankylosing spondylitis. It determined significant correlation between health-related quality of life (measured by Health Survey Short Form 36 and ASQoL) and the ASAS clinical responses
36. W Sterry JP Ortonne B Kirkham, et al. 2010 Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial BMJ 340 c147 10.1136/bmj.c147 20124563 This was a randomized, double-blind, multicenter, outpatient study that involved 752 patients. The purpose was to compare the efficacy over 12 weeks of two different etanercept regimens in treating the skin manifestations of psoriasis in patients who also have PsA and to evaluate efficacy and safety over an additional 12 weeks of open-label etanercept treatment
37. AA Qureshi P Dominguez KC Duffin, et al. 2008 Psoriatic arthritis screening tools J Rheumatol 35 1423 1425 18609737 This article explains the importance of development and validation of reliable screening tools for PsA
38. V Chandran A Gottlieb RJ Cook, et al. 2009 International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis Arthritis Rheum 61 1235 1242 10.1002/art.24562 19714610
39. J Zochling D van der Heijde R Burgos-Vargas 'ASsessment in AS' international working group; European League Against Rheumatism, et al. 2006 ASAS/EULAR recommendations for the management of ankylosing spondylitis Ann Rheum Dis 65 442 452 10.1136/ard.2005.041137 1:STN:280:DC%2BD287ktFGqsg%3D%3D 16126791